Cargando…
Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding
BACKGROUND: For patients with a normal coagulation system, who experience serious bleeding, sound evidence for recombinant activated factor VII (rFVIIa) as an effective haemostatic agent is only scarcely available so far from controlled clinical trials. In systematic reviews on the clinical use of r...
Autores principales: | Eller, P, Pechlaner, C, Wiedermann, CJ |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1373608/ https://www.ncbi.nlm.nih.gov/pubmed/16420687 http://dx.doi.org/10.1186/1477-9560-4-1 |
Ejemplares similares
-
The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
por: Altman, Raul, et al.
Publicado: (2010) -
Multiple drugs: Drugs ineffective and off-label use: case report
Publicado: (2022) -
Remdesivir/tocilizumab: Drug ineffective and off-label use: 2 case reports
Publicado: (2021) -
Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation
por: Hollis, Allison L., et al.
Publicado: (2016) -
Activated recombinant factor VII in management of bleeding in patients with thrombocytopenia
por: Shulutko, E, et al.
Publicado: (2006)